Brief: Adagene Announces First Patients Dosed In Global Phase 1 Clinical Trial Of Adg126, Lead Safebody™ Program
16/03/2021 12:57
March 16 (Reuters) - Adagene Inc ADAG.O :
* ADAGENE ANNOUNCES FIRST PATIENTS DOSED IN GLOBAL PHASE 1
CLINICAL TRIAL OF ADG126, LEAD SAFEBODY™ PROGRAM
Source text for Eikon: ID:nGNX9tG41S
Further company coverage: ADAG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adagene
See all newsBrief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate